Linear IgA bullous dermatosis: A review

被引:16
|
作者
Ingen-Housz-Oro, S. [1 ]
机构
[1] Hop Henri Mondor, Serv Dermatol, F-94000 Creteil, France
来源
关键词
Linear IgA bullous dermatosis; Treatment; PEMPHIGOID ANTIGEN; NC16A DOMAIN; DISEASE; CHILDHOOD; AUTOANTIBODIES; ADULTS; PATIENT; ERYTHROMYCIN; ASSOCIATION; ANTIBODIES;
D O I
10.1016/j.annder.2011.01.010
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background. - Linear IgA bullous dermatosis (LABD) is a rare auto-immune bullous disease occurring in adults or childhood. Objective. - Review of literature about physiopathology, triggering factors, clinical data and treatment of LABD. Methods. - Research on Medline and Embase database without any time limit until April 2010. Because of the lack of randomized therapeutic trials in LABD, retrospective series and case reports have been analyzed. Results. - LABD is due to IgA auto-antibodies typically directed against a proteolytic fragment of BP180 antigen, a 97 or 120 kD protein, and/or other components of dermal-epidermal junction. The disease may be either idiopathic or triggered by several medication, most often vancomycin, but also other antibiotics, non-steroid anti-inflammatory, anti-hypertensive and anti-epileptic drugs... Clinically, eruption is typical in childhood with cluster and herpetiform arrangement of blisters and involvement of evocative anatomical sites. In adults, eruption is polymorphic, very atypical presentations are described. Diagnosis is confirmed by direct immunofluorescence which shows linear IgA deposition on the basement membrane zone. Immunoblot and immunoelectron microscopy are evocative in case of diagnosis hesitation. LABD may be associated with some inflammatory bowel disorders. There is no increased risk of cancer or Lymphoma. For drug-induced LABD, withdrawal of the medication is followed by a quick healing of the lesions. Dapsone is quickly efficient in idiopathic LABD. Colchicine, sulfapyridine and systemic corticosteroids are used in case of intolerance or inefficiency of dapsone. Some authors emphasize the efficiency of first-intent antibiotics in LABD of childhood. Conclusion. - A triggering drug should be always suspected and stopped. Dapsone is the reference treatment in idiopathic cases of LABD. (C) 2011 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:214 / 220
页数:7
相关论文
共 50 条
  • [31] Linear IgA bullous dermatosis induced by moxifloxacin
    Gonul, M.
    Cakmak, S. Kulcu
    Yayla, D.
    Unal, T.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2014, 39 (01) : 78 - 80
  • [32] A newborn with bullous pemphigoid associated with linear IgA bullous dermatosis
    Akyn, M. A.
    Gunes, T.
    Akyn, L.
    Ohyama, B.
    Kontas, O.
    Hashimoto, T.
    ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA, 2009, 18 (02): : 66 - 70
  • [33] Management Options for Linear Immunoglobulin A (IgA) Bullous Dermatosis: A Literature Review
    Khan, Madiha
    Park, Lily
    Skopit, Stanley
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
  • [34] SCARRING LINEAR IGA BULLOUS DERMATOSIS IN ADULTS
    KURZ, K
    MAHRLE, G
    ZEITSCHRIFT FUR HAUTKRANKHEITEN H&G, 1986, 61 (20): : 1447 - &
  • [35] LINEAR IGA DAPSONE RESPONSIVE BULLOUS DERMATOSIS
    WOJNAROWSKA, F
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1980, 73 (05) : 371 - 373
  • [36] A PECULIAR CASE OF LINEAR IGA BULLOUS DERMATOSIS
    FULIGNI, A
    DIBLASI, A
    BORGOGNI, L
    PIMPINELLI, N
    MORETTI, S
    FABBRI, P
    ARCHIVES OF DERMATOLOGY, 1991, 127 (01) : 126 - 127
  • [37] INTERFERON ALFA FOR LINEAR IGA BULLOUS DERMATOSIS
    CHAN, LS
    COOPER, KD
    LANCET, 1992, 340 (8816): : 425 - 425
  • [38] Linear IgA bullous dermatosis in South India
    Ajithkumar, K
    Kurian, S
    Jacob, M
    Pulimood, S
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 1997, 36 (03) : 191 - 193
  • [39] Linear IgA bullous dermatosis induced by piroxicam
    Camilleri, M
    Pace, JL
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 1998, 10 (01) : 70 - 72
  • [40] The therapies for linear IgA bullous dermatosis of childhood
    Jablonska, S
    PEDIATRIC DERMATOLOGY, 1999, 16 (05) : 415 - 415